

From: noreply-dphimmunizations@ct.gov <noreply@everbridge.net>

Sent: Monday, February 14, 2022 11:51 AM

Subject: COVID-19 Vaccine Program (CoVP) Provider Bulletin, Week of February 14, 2022



DEPARTMENT OF PUBLIC HEALTH

Dear Connecticut COVID-19 Vaccine Providers,

This communication is being sent to all key contacts at provider organizations administering COVID-19 vaccine— please read this message in its entirety. Please feel free to share it with others in your organization who may benefit from the update. Note that all our communications are archived on our [web site](#).

Thank you for everything that you are doing to continue the roll-out of the COVID-19 vaccine program. Please continue your outreach to parents/individuals age 5 and older and encourage everyone to [stay up-to-date](#) with COVID-19 vaccines.

UPDATES

FDA Postpones Meeting to Discuss Authorization of Pfizer's Young Pediatric Vaccine (age 6 months through 4 years)

On Friday, the Food and Drug Administration's (FDA) [postponed their advisory committee meeting](#), originally scheduled to meet February 15th, to allow time to consider additional data. [Pfizer is extending their rolling EUA submission to the FDA](#) to include additional information regarding the ongoing evaluation of a third dose for this age group. The company expects to have three-dose protection data available in early April.

This will delay the previously communicated timeline for the young pediatric (6m-4y) rollout. We will provide further information when it becomes available. Additionally, we are awaiting further information regarding the status of existing pre-orders and will share with providers once it is available. We are not taking additional pre-orders at this time.

Action Required: Extended Deadline- COVID-19 Young Pediatric Vaccination Planning Survey –

The Department sent an email to all CoVP providers to assess readiness and anticipated barriers to vaccinate children under age 5. **Please review this [communication](#) and complete the survey at the link below by Friday, February 18, 2022.**

Survey Link: <https://www.surveymonkey.com/r/COVID-19YoungPediPlanning>

Updated CDC Guidance for COVID-19 Vaccination

[Interim Clinical Considerations for Use of COVID-19 Vaccines](#)

For people who are moderately or severely immunocompromised:

- An update that people who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster dose 3 months (instead of 5 months) after the last primary dose.
- An update that people who have received a single Johnson & Johnson's Janssen COVID-19 vaccine should receive one additional dose of an mRNA COVID-19 vaccine and one booster dose (preferably mRNA) for a total of 3 vaccine doses.
- A clarification of a current recommendation to confirm that those who have completed their primary series of 3 mRNA doses should receive an mRNA vaccine booster dose—to make a total of 4 doses.
- Emergency Use Instructions (EUI) to support these updates can be found [here](#).

For those who previously received passive COVID-19 antibody products:

- A simplification of existing guidance in that they do not need to wait for any period prior to COVID-19 vaccination.

These changes are designed to eliminate confusion related to COVID-19 vaccine recommendations for these populations and ensure that people are better protected from the potential severe consequences of COVID-19.

Recent Morbidity and Mortality Weekly Report (MMWRs)

Data from two CDC reports today show COVID-19 vaccine boosters remain safe and continue to be highly effective against severe disease over time and during Omicron and Delta waves.

In the first study¹, CDC reviewed data from two of its vaccine safety monitoring systems, [v-safe](#) and the [Vaccine Adverse Event Reporting System \(VAERS\)](#). They found that people 18 years and older who received the same mRNA vaccine brand for all their vaccinations experienced fewer adverse reactions following the booster dose, than they did after their second dose of mRNA vaccine. Ninety two percent (92%) of reports to VAERS were not considered serious, and headache, fever, and muscle pain were among the most commonly reported reactions. V-safe data found medical care was rarely received after a booster dose.

A second study² reveals that a third dose of mRNA vaccine continues to offer high levels of protection against severe disease, even months after administration, underscoring the importance of staying up to date when eligible after receiving a primary series. CDC examined data on 93,000 hospitalizations and 241,000 emergency department and urgent care visits across 10 states during the Delta and Omicron waves. In the study, about 10% of people were boosted and over 50% of people hospitalized were over 65 years old. During Omicron, vaccine effectiveness against hospitalization was 91% during the first two months after a third dose and remained high, at 78%, four or more months after a third dose.

[Boosters](#) are safe and effective, and CDC continues to recommend everyone 5 and older remain up to date with recommended COVID-19 vaccinations, to ensure optimal protection against hospitalizations and severe outcomes.

1. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022. Link [here](#).
2. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. Link [here](#).

REMINDERS

We are keeping information on many important reminders from past communications in the space below. To prevent this section from becoming too lengthy, what remains is selected carefully. All past communications are available [here](#).

<p>Upcoming Clinic Trainings and Office Hours</p>	<ul style="list-style-type: none"> • CoVP Update -- next meeting this Wednesday February 23 Provides CoVP Vaccinating Providers updates on the CoVP Program and Q&A with DPH staff. Every other Wednesday 9 am; Join: CoVP Update Meeting • The CoVP Enrollment Office Hours Provides information about the CoVP enrollment process in CT WiZ and Q&A with DPH staff. Mondays 12-12:30pm; Join: CoVP CT WiZ Enrollment Office Hours • Vaccine Storage and Handling Assessment For clinics who completed CoVP enrollment and received an invite to attend. Tuesdays 10-11am and 1-2pm & Thursdays 1-2pm; By invitation Only • VAMS & CT WiZ Live Helpdesk Office Hours Clinics can ask questions about VAMS and CT WiZ functionality to DPH staff. Tuesdays 9-10am; Join: VAMS Live Helpdesk Office Hours <p>Visit: VAMS Training and CT WiZ Training for enhancement release notes and training.</p>
<p>How to update your information in Vaccine Finder/Vaccines.gov</p>	<p>COVID-19 vaccine inventory counts must be reported to Vaccine Finder daily. This is required, regardless of whether your clinic is set as publicly displaying or private.</p> <p>Click here for instructions:</p> <ul style="list-style-type: none"> • If you need to make updates to your primary point of contact for Vaccine Finder: <ul style="list-style-type: none"> ○ Please update CT WiZ under: Clinic Tools – Clinic Information – Staff. Include a note in the ‘comments field’ of the update stating this is for a new point of contact for Vaccine Finder. Click here for the CT WiZ training.

	<ul style="list-style-type: none"> ○ Once completed, a registration link will be sent to the new contact from the CDC. If you do not receive this link, please email CARS_HelpDesk@cdc.gov to request they resend the registration link. ● When the primary vaccine coordinator creates their initial account in Vaccine Finder, they will be asked if they would like to report inventory for ‘all clinics’ under their organization or to report ‘clinics individually.’ <ul style="list-style-type: none"> ○ If you select the option to report for ‘all clinics’ under your organization, only your primary vaccine coordinator contact will receive a registration link. ○ If you select the option to report ‘individually’, your back-up vaccine coordinator will also receive a registration link. <p>If you choose to publicly display your clinic on Vaccines.gov (<i>optional</i>), please note that the shipping address listed in CT WIZ is what will be displayed on Vaccines.gov as your clinic location. Click here for training on how to publicly display your clinic on Vaccines.gov.</p>
--	---

COVID-19 Vaccine Administration Information

<p>Updated COVID-19 Vaccine Recommendations</p>	<ul style="list-style-type: none"> ● CDC recommends Staying Up to Date with vaccines by getting additional doses of vaccine when eligible for optimal protection against COVID-19. ● Individuals are considered fully vaccinated two weeks after they have received the last dose in their primary series. ● Children ages 5–11 with a weakened immune system can get an <i>additional dose</i> (3rd dose) of the Pfizer COVID-19 vaccine 28 days after their second shot. ● Now everyone 12 and older should get a booster if they are eligible for the best possible protection against Omicron. ● Anyone who received a Pfizer or Moderna primary series should get a booster 5 months after their second shot. ● FDA’s chart can be useful for helping patients understand when and which boosters are eligible. ● Immunocompromised individuals who received mRNA vaccines became eligible for an additional primary dose of an mRNA vaccine on August 13, 2021. These individuals are now eligible for a booster or fourth dose of COVID-19 vaccine after 3 months. ● CDC recommends COVID-19 vaccination for all people with a prior SARS-CoV-2 infection.
--	--

<p>Coadministration of COVID-19 and Influenza vaccines</p>	<p>You should administer COVID-19 and influenza vaccines without regard to timing (both live, attenuated and non-live influenza vaccines). This includes administration of COVID-19 and influenza vaccines on the same day, as well as administration at any time interval. (CDC Interim Clinical Considerations: Coadministration of COVID-19 and Influenza vaccines)</p>
---	--

[Tips for Communicating the Benefits of Influenza Vaccine during COVID-19](#)

COVID-19 Vaccine Product Information

Expiration Extensions

- Pfizer
- FDA extended shelf-life for Pfizer Pediatric vaccine (Orange cap, 5-11 YO, diluent required) and Adol/Adult Tris (Gray Cap, age 12+, no diluent) to 9 months from date of manufacture when stored in an ultra-cold freezer. This approval may be found at [Healthcare Providers for 5-11 years of age, orange cap \(must dilute\) \(fda.gov\)](#); [Healthcare Providers for 12 years of age and older, gray cap \(no dilution\) \(fda.gov\)](#)) and takes effect immediately. **This extension applies to frozen (ULT) inventories only.** Date of expiration always falls on the last day of the month
- Moderna
- FDA authorized an extension of the shelf life for certain lots of the Moderna COVID-19 vaccine. REMEMBER: vials must be maintained in the frozen state for the extension to be applicable (extension does not apply to thawed vials)
 - Look up expiration date by scanning QR code located on the carton or use the company's [expiration date lookup feature](#) on its website.
 - Visit [CDC's Vaccine Lot Number and Expiration Date](#) webpage and complete the registration form to request access or contact IISInfo@cdc.gov.

Report Vaccine Temperature Excursions and Wastage

Report vaccine temperature excursions and vaccines wasted to the [Helpdesk](#) by following the prompts and submitting a ticket.

When reporting expired doses to the [Helpdesk](#), please select the "Report Vaccine Wastage" ticket option, then select "Other" as the wastage reason and type "Expiration" in the text box when prompted. Please make sure that inventory is updated in Vaccine Finder, VAMS, or CT WiZ as appropriate.

CT WiZ

CT WiZ Vaccine Inventory Management

- [CVP Vaccine Inventory Management \(ct.gov\)](#)
- Moderna Inventory and Booster Adjustments in CT WiZ
 - Moderna Wastage Reporting in CT WiZ

Ensure Best Practice by Checking CT WiZ Before Vaccinating

Prior to administering any vaccine, including the COVID-19 vaccine, it is important that a recipient's prior vaccine history be referenced in the Immunization Information System (CT WiZ); best clinical practice is to verify that the recommended interval has elapsed since a previous dose of vaccine and that the preferred brand of vaccine be administered.

	<ul style="list-style-type: none"> • If your clinic established bi-directional data exchange, you can query CT WiZ for the patient immunization record electronically from your EHR. • Every CoVP enrolled clinic can look up the patient immunization record in the CT WiZ user interface. Those who signed the CoVP Provider Agreement and the primary and back-up vaccine coordinator already have CT WiZ access. • If your staff need access to CT WiZ, request a username and select the 'Clinic Access' role. Access to CT WiZ is defined in EXECUTIVE ORDER NO. 13C. • If you need support, please submit a Helpdesk ticket.
<p>COVID-19 SMART Health Card</p>	<p>The COVID-19 vaccination record SMART Health Card / QR code is available in the CT WiZ Immunization Information System (IIS) and the CT WiZ Public Portal.</p> <ul style="list-style-type: none"> • Recipients can access their own records by using the CT WiZ Public Portal. For security, this public portal uses 'two-factor authentication' to verify identify. • If recipients require support with accessing their vaccination record, they can complete the online request form or call our Immunization Program phone 860-509-7929 during business hours. <p>For FAQs, visit: CT WiZ Access My Immunization Record. This webpage has been updated with new FAQs about the SMART Health Card.</p> <p>Tip for Clinics: Ensuring your recipient's contact information is current at each visit (such as cell phone and email) will be helpful to enable recipients to access their own (or their minor child's) record in the CT WiZ Public Portal.</p>
<p>Replacement CDC COVID Vaccination Cards</p>	<p><i>Recommendation:</i> Post your procedure for recipients to request replacement cards, in a location visible to recipients at your clinic as well as on your website. If your clinic needs additional CDC COVID-19 Vaccination Cards, contact DPH.Immunizations@ct.gov.</p>
<p>Post Notice to Patients About Reporting to CT WiZ at CoVP Clinics</p>	<p>All clinics enrolled in the CoVP must post the Notice to Patients About Reporting to CT WiZ, to let vaccine recipients know their records are being reported to CT WiZ. If you are reporting through VAMS, this data is transmitted to CT WiZ.</p>
<p>CDC Resource Links</p>	
<p>COVID-19 clinical materials, including product-specific trainings, guidance and infographics, are here: COVID-19 Vaccination Clinical and Professional Resources CDC</p>	

COVID-19 Vaccines

[Different COVID-19 Vaccines](#)

[Quick Reference Guide](#)

[Product Information Guide for COVID-19 Vaccines and Ancillary Kits/Associated Products](#) (11/3)

[The Ancillary Redistribution Gadget for Healthcare \(ARGH\) Tool](#) (11/4)

Vaccine Safety

[Enroll Your Dependent in v-safe](#)

[COVID-19 Science Brief: *Infection vs Vaccine Induced Immunity*](#)

[COVID-19 Vaccine Effectiveness Research](#)

Vaccine Administration

[Vaccine Administration Resource Library | CDC](#) Includes information Vaccine administration e-learn with CE for pharmacists, infographics for identifying injection sites, short video demonstration injection and holding children.

[Pink book: Vaccine Administration | CDC](#) includes strategies to decrease anxiety and procedural pain.

[COVID-19 Vaccine Webinar Series | CDC.](#)

[COVID-19 Vaccines While Pregnant or Breastfeeding](#)

[COVID-19 Vaccine Booster Shots](#)

[COVID-19 Vaccines for Children and Teens](#)

[Quick Conversation Guide on COVID-19 Vaccines for Children](#)

[Resources to Promote the COVID-19 Vaccine for Children & Teens](#)

[Using the COVID-Vac Tool to Assess Your COVID-19 Vaccination Clinic Staffing and Operations Needs](#)

Thank you for all your ongoing work and support of our COVID-19 vaccine roll-out in Connecticut.

For the CT DPH Immunization Program, visit: [Contact Us](#)

For the COVID-19 webpage, visit: [COVID-19 Vaccine Program](#)

If you would like to unsubscribe from these communications, please send an email to Dph.immunizations@ct.gov with the subject line “Unsubscribe from COVID-19 Program communications”.